Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 2/2007

01-12-2007 | Case Report

Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis

Authors: Kenan Aksu, Ayhan Donmez, Yesim Ertan, Gokhan Keser, Vedat Inal, Gonca Oder, Murat Tombuloglu, Yasemin Kabasakal, Eker Doganavsargil

Published in: Rheumatology International | Issue 2/2007

Login to get access

Abstract

It has been well known that anti-TNF drugs might increase lymphoma risk in rheumatoid arthritis (RA), where the rate of lymphoma has already been increased. However, unlike RA, an increased rate of lymphoma has not been reported in ankylosing spondylitis (AS). Hereby, we present a case with AS developing Hodgkin’s lymphoma (HL) following 6 months of etanercept treatment. Pathological analysis revealed mixed cellular type of HL. Although we report a single case, it should be kept in mind that anti-TNF drugs might cause lymphoma development not only in RA, but also in AS.
Literature
1.
Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 6(Suppl 28):S152–S157
2.
Desai SB, Furst DE (2006) Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 4:757–790CrossRef
3.
Bernatsky S, Ramsey-Goldman R, Clarke A (2006) Malignancy and autoimmunity. Curr Opin Rheumatol 8:129–134CrossRef
4.
Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N (2006) Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case–control study. Ann Rheum Dis 65:1184–1187PubMedCrossRef
5.
Jantunen E, Myllykangas-Luosujarvi R, Kaipiainen-Seppanen O, Nousiainen T (2000) Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis. Rheumatology (Oxford) 5:563–564CrossRef
6.
Khan SY, Hutchinson DG (2004) Primary synovial non-Hodgkin’s lymphoma in association with ankylosing spondylitis. Rheumatology (Oxford) 43:391CrossRef
7.
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151–3158PubMedCrossRef
8.
Thomas RK, Wolf J, Diehl V (2004) Part I-Hodgkin’s lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 5:11–18PubMedCrossRef
9.
Weiss LM, Strickler JG, Warnke RA, et al (1987) Ebstein-Barr viral DNA in tissues of Hodgkin’s disease. Am J Pathol 129:86–91PubMed
10.
Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740–1751PubMedCrossRef
Metadata
Title
Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis
Authors
Kenan Aksu
Ayhan Donmez
Yesim Ertan
Gokhan Keser
Vedat Inal
Gonca Oder
Murat Tombuloglu
Yasemin Kabasakal
Eker Doganavsargil
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0391-9

Other articles of this Issue 2/2007

Rheumatology International 2/2007 Go to the issue

Original Article

Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies

Review

Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol

Original Article

The association of DRB1*04 share epitope alleles and tumor necrosis factor-alpha gene polymorphism (−863) with susceptibility to rheumatoid arthritis in Thai

Letter to the Editor

Letter to the Editor

Original Article

Microvascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: relationship to soluble adhesion molecules and extraarticular manifestations

Case Report

Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits